XCSport体育
About Henlius
Company Profile
Corporate Culture
Honor
XCSport体育:Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
XCSport体育:Clinical Trial
Science & Technology
R&D Result
XCSport体育:Innovation Centre
Technology Platform
XCSport体育:Quality Management
XCSport体育:Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
XCSport体育:Multi-media
XCSport体育:Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
XCSport体育:Clinical Trial
Science & Technology
XCSport体育:R&D Result
XCSport体育:Innovation Centre
XCSport体育:Technology Platform
Quality Management
XCSport体育:Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
XCSport体育:Media Enquiry
Careers
XCSport体育:Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
XCSport体育:Customer Message
Privacy
XCSport体育:Legal Statement
XCSport体育:Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
XCSport体育:Popular Science
XCSport体育:Highlights
Download
Media Reports
XCSport体育:Media Enquiry
2019-06-04
Henlius will Initiate Phase I Clinical Trialof HLX20 (Anti-PD-L1 Antibody) in Australia
2019-05-24
Important News! ruizhen.netpleted Its First Phase III Study of HLX01(Rituximab Injection)
2019-05-22
Henlius Formed Scientific Advisory Board (SAB)
2019-05-10
China's Global Investment Push Opens Doors for Domestic Biotechs
2019-03-01
Hail! Shanghai Henlius Biotech, Inc. is Honored as the Annual Preeminence of Asia Biotech of 2017
2019-01-22
Innovation-driven Development | Market Capitalization of Henlius Biotech Hits CNY 10 Billion
1
2